GLP-1 Pipeline & Medicare Coverage

Oral orforglipron (Foundayo) approved April 2026 with 50% better weight loss than oral semaglutide. Retatrutide BLA expected Q1 2027 with 28-30% weight loss; Eli Lilly now offering early access for treatment-resistant patients, with 28.7% weight loss and osteoarthritis pain relief signal. Medicare coverage begins July 2026 at $50/month. Pipeline includes survodutide and apitegromab.